Enara Bio Company
Ervaxx is illuminating the immune interface to develop new cancer therapies.
Technology:
Tumor-Specific Antigens
Industry:
Tumor-Specific Antigens
Headquarters:
London, England, United Kingdom
Founded Date:
2016-01-01
Employees Number:
11-50
Funding Status:
Early Stage Venture
Investors Number:
2
Total Funding:
17500000
Estimated Revenue:
$1M to $10M
Last Funding Date:
2019-11-06
Last Funding Type:
Series A
Register and Claim Ownership